Thera-SAbDab

MIROMAVIMAB

>   Structural Summary
TherapeuticMiromavimab
TargetRabies Virus Strain ERA GP Ectodomain Epitope G-II
Heavy ChainQVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS
Light ChainDIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb (Mouse)
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)NFD
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedCandila Healthcare
Conditions ApprovedRabies
Conditions Activena
Conditions Discontinuedna
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy